ClinicalTrials.gg
Status unknownNCT05651074Updated Jan 31, 2023

Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects

A Phase 1 interventional study of Vicagrel and omeprazole in Healthy Subjects, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-31.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the effects of omeprazole on the PK and PD of a single dose of vicagrel in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to give written before study, and fully understand the study content, process and possible adverse reactions;
  2. Able to complete the study in compliance with the protocol;
  3. Subject (including partner) is willing to voluntarily take effective measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
  4. Male and female subjects between the ages of 18 and 45 years, inclusive;
  5. At least 50 kg for male subjects, 45 kg for female subjects, with a (BMI= Weight/Height2) between 18-28 kg/m2, inclusive;
  6. With normal or clinically insignificant abnormal results of physical examination and vital signs test;
  7. CYP2C19 normal metabolizers (CYP2C19*1/*1).

Exclusion criteria

Exclusion Criteria:

  1. More than 5 cigarettes per day on average within 3 months before the study;
  2. History of sensitivity to drugs similar to the study drug or have high sensitivity to clopidogrel, or to omeprazole, other benzimidazoles, or any , allergic constitution (e.g. allergy to various drugs and foods);
  3. History of drug abuse, drug use, alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL beer, 25 mL spirit or 100 mL wines);
  4. Donation or loss of a significant volume of blood (> 450 mL) within 3 months prior to screening;
  5. Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;
  6. Consumption of any special diet (such as grapefruit, pitaya, mango, pomelo, etc.) or subjects have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 14 days prior to receiving study drug;
  7. Intake of any drug which Have taken strong inhibitors and/or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and 3A5) within 28 days before the first medication, and strong inhibitors of liver metabolic enzymes such as: ciprofloxacin, clopidogrel, Itraconazole, ketoconazole, ritonavir, troleandomycin, etc., strong inducers of liver metabolism enzymes such as: rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc. (For details see Appendix 6);
  8. Recent major changes in diet or exercise habits;
  9. Use of an drug or product, or participation in a drug research study within 3 months prior to receiving study drug;
  10. History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption;
  11. Suffering from any diseases that may increase the risk of bleeding, such as hemorrhoids, acute gastritis, stomach and duodenal ulcers, Thrombocytopenic Purpura and hemophilia, etc;
  12. Family history of coagulation or bleeding disorders (e.g., hemophilia)/symptoms (e.g., vomiting blood, black stools, severe or recurrent nosebleeds, coughing up blood, significant hematuria, or intracranial hemorrhage) or suspected vascular malformations, such as aneurysms or early onset strokes, in the individual or in their immediate family;
  13. A 12-lead abnormality;
  14. Positive test results of blood pregnancy or subject is lactating for female subjects;
  15. Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;
  16. Positive test results for viral hepatitis (including and C), antibody or syphilis antibody;
  17. Acute illness or concomitant medication from screening to the first dosing of study medication;
  18. Consumption of chocolate or any food or beverages containing caffeine or (rich containing) xanthine within 48 h prior to receiving the first dosing of study medication;
  19. Consumption of any product containing alcohol within 24 h prior to receiving the first dosing of study medication, or positive results from a screen for alcohol;
  20. Positive results from a screen for urine drug test (Morphine, marijuana);
  21. Subjects were vaccinated within 4 weeks prior to screening, or planned to be vaccinated during the trial;
  22. Any condition which in the opinion of Investigator is not suitable for subjects to participate in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Vicagrel and omeprazole

    D1 single dose of vicagrel was administered. Omeprazole administration was started on D4, once daily for 5 days, and a single dose of vicagrel and omeprazole coadministration on day 9.

    Drug: Vicagrel and omeprazole

Interventions

  • DrugVicagrel and omeprazole

    Drug pages: Sumecigrel · Omeprazole

    18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets

06

What researchers measure

Primary outcomes

  1. Inhibition of platelet aggregation [IPA] evaluated in healthy subjects to treatment with vicagrel

    Time frame: Day 2 of each period

  2. Platelet reactivity index [PRI] evaluated in healthy subjects to treatment with vicagrel

    Time frame: Day 2 of each period

  3. maximum plasma concentration (Cmax)

    Time frame: Up to 48 hours postdose on Day 3 for each period

  4. Area under the concentration-time curve (AUC)

    Time frame: Up to 48 hours postdose on Day 3 for each period

Secondary outcomes

  1. Assess the safety of a single dose of vicagrel and a combination of vicagrel and omeprazole in healthy subjects by assessment of adverse events and symptoms and physical examination, clinical laboratory tests, vital signs,12-ECG.

    Time frame: Day1-Day11

07

Study locations

1 of 1 sites recruiting
  • Phase I Clinical Research Center of The First Hospital of Jilin University
    Chang chun, Jilin, China
    Recruiting
    • Zhang Hong · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Feb 2023, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2022
First posted
Dec 14, 2022
StartActual
Nov 14, 2022
Primary completionEst.
Feb 2023
CompletionEst.
Apr 2023
Last update
Jan 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05651074
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Nov 14, 2022
Primary completion
Feb 2023 (estimated)
Completion
Apr 2023 (estimated)
Last update
Jan 31, 2023

Study contacts

Wang Fei, 130021
Contact
wangfei5780@126.com
0431-88786014

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sumecigrel · Omeprazole

Start the discussion